Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1070-1078

  Dai, Haibin ^a,b,c   Yu, Zhanyang ^b,c   Fan, Xiang ^b,c   Liu, Ning ^b,c   Yan, Min ^a   Chen, Zhong ^a   Lo, Eng H ^b,c   Hajjar, Katherine A ^d   Wang, Xiaoying ^b,c  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Advanced glycation end product; Annexin A2; Fibrinolytic activity; Human brain microvascular endothelial cells; Hyperglycaemia

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; ADVANCED GLYCATION END PRODUCT; LIPOCORTIN 2; MESSENGER RNA; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANNEXIN A2; BRAIN; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBRINOLYSIN; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MICROCIRCULATION; RECOMBINANT PROTEINS; RNA, MESSENGER; S100 PROTEINS;

EID: 84878650809     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0944     Document Type: Article

References (41)

1. Haratz S, Tanne D. Diabetes, hyperglycaemia and the management of cerebro-vascular disease. Curr Opin Neurol 2011; 24: 81-88.
2. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105 (Suppl 1): S43-54.
3. Tjarnlund-Wolf A, Brogren H, Lo EH, et al. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012; 43: 2833-2839.
4. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
5. Hajjar KA. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991; 266: 21962-21970.
6. Flood EC, Hajjar KA. The annexin A2 system and vascular homeostasis. Vascul Pharmacol 2011; 54: 59-67.
7. Ishii H, Yoshida M, Hiraoka M, et al. Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 2001; 89: 1240-1245.
8. Ishii H, Yoshida M, Hajjar KA, et al. Potential role of recombinant annexin II in diabetic vascular injury. Ann N Y Acad Sci 2001; 947: 308-311.
9. Zhu H, Fan X, Yu Z, et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab 2010; 30: 1137-1146.
10. Fan X, Yu Z, Liu J, et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke 2010; 41: S54-58.
11. Walvick R P, Bratane BT, Henninger N, et al. Visualisation of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy. Stroke 2011; 42: 1110-1115.
12. Ghitescu LD, Gugliucci A, Dumas F. Actin and annexins I and II are among the main endothelial plasmalemma-associated proteins forming early glucose ad-ducts in experimental diabetes. Diabetes 2001; 50: 1666-1674.
13. Yamagishi S, Nakamura K, Matsui T, et al. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovasc Ther 2008; 26: 50-58.
14. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci 2011; 121: 43-55.
15. Gugliucci A, Ghitescu L. Is diabetic hypercoagulability an acquired annexin-opathy? Glycation of annexin II as a putative mechanism for impaired fibrinoly-sis in diabetic patients. Med Hypotheses 2002; 59: 247-251.
16. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313-1317.
17. Nagai R, Matsumoto K, Ling X, et al. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 2000; 49: 1714-1723.
18. Diaz VM, Hurtado M, Thomson TM, et al. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004; 53: 993-1000.
19. Choi YG, Lim S. Characterisation of anti-advanced glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products. J Immunoassay Immunochem 2009; 30: 386-399.
20. Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-305.
21. Hajjar KA, Acharya SS. Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci 2000; 902: 265-271.
22. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260-273.
23. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
24. Zorio E, Gilabert-Estelles J, Espana F, et al. Fibrinolysis: the key to new patho-genetic mechanisms. Curr Med Chem 2008; 15: 923-929.
25. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
26. Shen GX. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. Int J Mol Med 1998; 1: 399-408.
27. Robbie LA, Booth NA, Brown AJ, et al. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-545.
28. Martin-Paredero V, Vadillo J, Diaz J, et al. Fibrinogen and fibrinolysis in blood and in the arterial wall: its role in advanced atherosclerotic disease. Cardiovasc Surg 1998; 6: 457-462.
29. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
30. Lemkes BA, Hermanides J, Devries JH, et al. Hyperglycaemia: a prothrombotic factor? J Thromb Haemost 2010; 8: 1663-1669.
31. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/ tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-21197.
32. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasmi-nogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
33. Pandolfi A, Iacoviello L, Capani F, et al. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia 1996; 39: 1425-1431.
34. Ziegler O, Drouin P. Haemobiological activity of gliclazide in diabetes mellitus. Diabetes Res Clin Pract 1991; 14 (Suppl 2): S83-89.
35. Pandolfi A, Giaccari A, Cilli C, et al. Acute hyperglycaemia and acute hyperin-sulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 2001; 38: 71-76.
36. Choi KS, Fitzpatrick SL, Filipenko NR, et al. Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer. J Biol Chem 2001; 276: 25212-25221.
37. He KL, Deora AB, Xiong H, et al. Endothelial cell annexin A2 regulates polyubi-quitination and degradation of its binding partner S100A10/p11. J Biol Chem 2008; 283: 19192-19200.
38. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999; 9: 128-138.
39. Dejouvencel T, Doeuvre L, Lacroix R, et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115: 2048-2056.
40. He KL, Sui G, Xiong H, et al. Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2. J Biol Chem 2011; 286: 15428-15439.
41. Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96: 4212-4215.